tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2022 Apr 29;1-10.
doi: 10.1080/21645515.2022.2058304. Online ahead of print.
Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
Daniel Molnar[SUP] 1 [/SUP], Anastassia Anastassopoulou[SUP] 2 [/SUP], Barbara Poulsen Nautrup[SUP] 3 [/SUP], Ruprecht Schmidt-Ott[SUP] 4 [/SUP], Martin Eichner[SUP] 5 6 [/SUP], Markus Schwehm[SUP] 7 [/SUP], Gael Dos Santos[SUP] 1 [/SUP], Bernhard Ultsch[SUP] 8 [/SUP], Rafik Bekkat-Berkani[SUP] 9 [/SUP], Alfred von Krempelhuber[SUP] 8 [/SUP], Ilse Van Vlaenderen[SUP] 10 [/SUP], Laure-Anne Van Bellinghen[SUP] 10 [/SUP]
Affiliations
Abstract
Seasonal influenza causes many cases and related deaths in Europe annually, despite ongoing vaccination programs for older adults and people at high-risk of complications. Children have the highest risk of infection and play a key role in disease transmission. Our cost-utility analysis, based on a dynamic transmission model, estimated the impact of increasing the current vaccination coverage with inactivated quadrivalent influenza vaccine in Germany to all (healthy and high-risk) children under 5 years of age (40% uptake), or under 18 years (40% uptake), or only high-risk children under 18 years (90% uptake). Eight influenza complications were modeled, hospitalization and death rates were based on age and risk status. All three vaccination strategies provided more health benefits than the existing vaccination situation, reducing influenza cases, complications, hospitalizations and deaths across the entire population. The strategy targeting all children under 5 years was highly cost-effective (€6/quality-adjusted life-year gained, payer perspective). The other strategies were cost saving from the payer and societal perspectives. The vaccination strategy targeting all children under 18 years was estimated to provide the most health benefits (preventing on average 1.66 million cases, 179,000 complications, 14,000 hospitalizations and 3,600 deaths due to influenza annually) and the most cost savings (annually €20.5 million and €731.3 million from payer and societal perspectives, respectively). Our analysis provides policy decision-makers with evidence supporting strategies to expand childhood influenza vaccination, to directly protect children, and indirectly all other unvaccinated age groups, in order to reduce the humanistic and economic burden on healthcare systems and society.
Keywords: Children; Germany; economic model; quadrivalent influenza vaccine; seasonal influenza; uptake.
. 2022 Apr 29;1-10.
doi: 10.1080/21645515.2022.2058304. Online ahead of print.
Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
Daniel Molnar[SUP] 1 [/SUP], Anastassia Anastassopoulou[SUP] 2 [/SUP], Barbara Poulsen Nautrup[SUP] 3 [/SUP], Ruprecht Schmidt-Ott[SUP] 4 [/SUP], Martin Eichner[SUP] 5 6 [/SUP], Markus Schwehm[SUP] 7 [/SUP], Gael Dos Santos[SUP] 1 [/SUP], Bernhard Ultsch[SUP] 8 [/SUP], Rafik Bekkat-Berkani[SUP] 9 [/SUP], Alfred von Krempelhuber[SUP] 8 [/SUP], Ilse Van Vlaenderen[SUP] 10 [/SUP], Laure-Anne Van Bellinghen[SUP] 10 [/SUP]
Affiliations
- PMID: 35486410
- DOI: 10.1080/21645515.2022.2058304
Abstract
Seasonal influenza causes many cases and related deaths in Europe annually, despite ongoing vaccination programs for older adults and people at high-risk of complications. Children have the highest risk of infection and play a key role in disease transmission. Our cost-utility analysis, based on a dynamic transmission model, estimated the impact of increasing the current vaccination coverage with inactivated quadrivalent influenza vaccine in Germany to all (healthy and high-risk) children under 5 years of age (40% uptake), or under 18 years (40% uptake), or only high-risk children under 18 years (90% uptake). Eight influenza complications were modeled, hospitalization and death rates were based on age and risk status. All three vaccination strategies provided more health benefits than the existing vaccination situation, reducing influenza cases, complications, hospitalizations and deaths across the entire population. The strategy targeting all children under 5 years was highly cost-effective (€6/quality-adjusted life-year gained, payer perspective). The other strategies were cost saving from the payer and societal perspectives. The vaccination strategy targeting all children under 18 years was estimated to provide the most health benefits (preventing on average 1.66 million cases, 179,000 complications, 14,000 hospitalizations and 3,600 deaths due to influenza annually) and the most cost savings (annually €20.5 million and €731.3 million from payer and societal perspectives, respectively). Our analysis provides policy decision-makers with evidence supporting strategies to expand childhood influenza vaccination, to directly protect children, and indirectly all other unvaccinated age groups, in order to reduce the humanistic and economic burden on healthcare systems and society.
Keywords: Children; Germany; economic model; quadrivalent influenza vaccine; seasonal influenza; uptake.